The global lung cancer liquid biopsy market is poised for robust growth, with a projected market size of US$ 1,900.5 million by 2032, up from US$ 824.7 million in 2025. This growth is driven by a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032. Liquid biopsy is increasingly seen as a non-invasive alternative to traditional tissue biopsy, offering substantial advantages in terms of early detection, personalized treatment, and monitoring disease progression. This technology involves analyzing blood samples to detect biomarkers such as cell-free DNA (cfDNA), circulating tumor cells (CTCs), and exosomes, enabling the early identification of lung cancer and facilitating less invasive treatments.
Key Industry Highlights
The lung cancer liquid biopsy market has witnessed significant technological innovations and advancements. In 2024, the dominance of next-generation sequencing (NGS)-based multi-gene parallel analysis made a significant impact on global market share, owing to its ability to provide comprehensive genomic profiling of lung cancer. Furthermore, the introduction of new technologies such as Whole Genome Amplification (WGA) and Digital PCR is enhancing the sensitivity and precision of liquid biopsy tests, allowing for earlier detection of lung cancer.
North America leads the market, accounting for a substantial share due to the high prevalence of lung cancer and its advanced healthcare infrastructure. Meanwhile, the Asia-Pacific region is emerging as a rapidly growing market, particularly in countries like China and Japan, where there is a rising adoption of liquid biopsy technologies.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35195
Market Dynamics
Driver – Advances in Liquid Biopsy Technologies and Biomarker Discovery
Significant progress in liquid biopsy technologies and biomarker discovery is fueling the growth of the lung cancer liquid biopsy market. The identification of various biomarkers, such as microRNAs, mutated genes, and proteins, plays a crucial role in the early detection and monitoring of lung cancer. These discoveries have improved the sensitivity and specificity of liquid biopsy tests, making them more effective in clinical settings.
Key players are actively contributing to the evolution of lung cancer detection. For example, BioMark Diagnostics initiated the enrollment of patients for its lung cancer screening study in January 2023, combining metabolomics liquid biopsy with radiomics and genetic biomarkers to enhance lung cancer screening accuracy. Similarly, Freenome launched the PROACT LUNG clinical study in December 2023, focusing on integrating blood-based biomarkers with cancer-common markers from its multiomics platform to develop more precise and personalized diagnostic tools.
Restraint – Limited Sensitivity of Biomarkers in Detecting Early-Stage Cancers
Despite their many advantages, liquid biopsy technologies face certain challenges, especially in detecting early-stage lung cancers. At the onset of lung cancer, tumor-derived biomarkers like ctDNA or CTCs are often present in low concentrations, making it difficult to achieve accurate results with liquid biopsy. Additionally, the complexity and diversity of tumor biology contribute to variability in biomarker expression, which further complicates the early detection of cancers. While advancements in biomarker discovery continue to improve test sensitivity, these challenges remain a significant barrier to broader adoption.
Opportunity – Growing Demand for Liquid Biopsy as a Companion Diagnostic Tool for Targeted Lung Cancer Treatment
The growing shift towards personalized medicine and targeted therapies for lung cancer presents a considerable opportunity for the liquid biopsy market. Liquid biopsy is increasingly used as a companion diagnostic (CDx) tool to identify patients most likely to benefit from targeted therapies such as EGFR inhibitors and ALK inhibitors. These tests help clinicians choose the right treatment plans for individual patients, thus improving therapeutic outcomes.
In November 2024, Foundation Medicine Inc. received U.S. FDA approval for its FoundationOne® Liquid CDx as a companion diagnostic for TEPMETKO® (tepotinib), which is used in the treatment of non-small cell lung cancer (NSCLC). Such advancements illustrate the growing role of liquid biopsy in routine clinical practice, providing timely, non-invasive, and personalized treatment options for lung cancer patients.
Category-wise Analysis
Product Insights
Consumables, including kits and reagents, accounted for 71.2% of the revenue share in 2024. This is largely due to their recurrent usage in diagnostic procedures, where they are crucial for sample collection, processing, and analysis. As liquid biopsy technologies become more widespread in lung cancer detection, the demand for consumables such as test kits, reagents, and assay components is expected to grow significantly.
Technology Insights
In terms of technology, multi-gene parallel analysis (NGS) led the market in 2024, commanding 75.2% of the market share. NGS technology enables the simultaneous analysis of multiple genetic mutations, making it highly effective in identifying a wide range of genetic alterations associated with lung cancer. This approach also facilitates the precise targeting of therapies based on the patient’s genetic profile, making NGS the preferred method for both diagnostic and research applications.
Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35195
Regional Insights and Trends
North America Lung Cancer Liquid Biopsy Market Trends
North America holds a dominant position in the global lung cancer liquid biopsy market, capturing 47.8% of the market share in 2024. The U.S., in particular, has seen a rising incidence of lung cancer, with approximately 226,650 new cases expected in 2025. The high demand for advanced diagnostic technologies, combined with substantial investments in research and healthcare infrastructure, continues to drive market growth in the region. For example, in February 2024, Roche invested USD 254 million in Freenome to advance its multiomics platform and develop blood tests for early cancer detection.
Europe Lung Cancer Liquid Biopsy Market Trends
Europe is the second-largest regional market, accounting for 28.6% of the global share in 2024. The region’s market growth is attributed to significant investments in research and technology, as well as strong collaborations between healthcare providers, academic institutions, and biotechnology companies. Countries such as Germany and the U.K. are leading the adoption of liquid biopsy technologies, supported by favorable regulatory environments and reimbursement policies. In March 2024, Guardant Health partnered with The Royal Marsden to expand the use of liquid biopsy technology in lung cancer treatment through the NHS England study.
Asia-Pacific Lung Cancer Liquid Biopsy Market Trends
The Asia-Pacific region is expected to grow at a CAGR of 15.6% during the forecast period, driven by increasing lung cancer incidences in countries such as China and India. In India, local biotech startups are focusing on affordable, region-specific diagnostic solutions, supported by government initiatives to improve cancer detection. Furthermore, Johnson & Johnson’s “India Detects to Defeat” campaign, launched in November 2024, highlights the growing importance of early detection and testing for lung cancer in the country.
Competitive Landscape
The global lung cancer liquid biopsy market is highly competitive, with several leading players focusing on innovation and expanding their product portfolios through strategic partnerships and collaborations. Companies are also investing heavily in research and development to create more advanced and precise liquid biopsy solutions.
Key Industry Developments
In January 2025, Viz.ai partnered with Guardant Health to combine AI and genomics through the Viz.ai One platform, aiming to enhance lung cancer detection and ensure timely, personalized care. Similarly, in December 2024, Guardant Health joined forces with Boehringer Ingelheim to seek regulatory approval for the Guardant360® CDx liquid biopsy as a companion diagnostic for zongertinib, a targeted tyrosine kinase inhibitor for NSCLC.
Key Players
Key players in the lung cancer liquid biopsy market include Bio-Rad Laboratories, Agilent Technologies, NeoGenomics Laboratories, QIAGEN, Thermo Fisher Scientific, Guardant Health, Illumina, and Foundation Medicine, among others. These companies are actively contributing to market growth through product innovations, strategic collaborations, and the development of cutting-edge technologies for more effective lung cancer diagnosis and treatment.
Market Segmentation
The lung cancer liquid biopsy market can be segmented based on product type, technology, application, and region. Product segmentation includes consumables, kits, reagents, and assay components, while technology segmentation includes NGS, PCR, and microarrays. Regional segmentation covers North America, Europe, Asia-Pacific, and other regions.
Recent Developments
In January 2025, Viz.ai partnered with Guardant Health to advance lung cancer detection using AI and genomics.
In December 2024, Guardant Health and Boehringer Ingelheim collaborated to commercialize the Guardant360® CDx as a companion diagnostic tool for targeted therapy.
In April 2024, City of Hope and DELFI Diagnostics launched a lung cancer screening initiative in underserved Los Angeles communities.
Future Outlook
The future of the lung cancer liquid biopsy market is promising, with continuous advancements in technology, increasing demand for personalized treatment options, and growing global healthcare infrastructure. As liquid biopsy solutions become more accessible and affordable, they are expected to play a pivotal role in revolutionizing lung cancer diagnosis and treatment, offering greater precision and improving patient outcomes across the globe.
